Latest Current Report
Filed: 2026-04-21
Key Insights
- Aligos secured a $25 million upfront payment from Amoytop for exclusive rights to develop and commercialize pevifoscorvir sodium in Greater China (mainland China, Taiwan, Hong Kong, Macau) for Hepatitis B/D treatment, providing near-term cash and validating the asset's commercial potential in a major market.
- The deal structure includes up to $420 million in future development, regulatory, and commercial milestones plus high single-digit tiered royalties, offering significant upside if Amoytop successfully advances the compound through development and commercialization in the territory.
- Aligos retains key rights to manufacture and develop the Licensed Product outside the Territory and Field, maintains access to Amoytop's manufacturing improvements on a non-exclusive basis, and has a 7-year right of first negotiation for novel formulations, preserving strategic flexibility and global optionality.